Skip to content
Assyro AI
Orange Book drug · Brand (NDA)

Envarsus XR

Tacrolimus

RLDNDA 206406 3 strengths Veloxis Pharms Inc
Approved
Jul 10, 2015
Strengths
3
Listed patents
10

What does the FDA Orange Book show for Envarsus XR?

Envarsus XR contains Tacrolimus and is the new drug FDA Orange Book record for NDA 206406. The application has 3 presentations with strength, dosage-form, route, status, RLD/RS, TE, patent, and exclusivity context. Current inventory and clinical labeling are not established without an application-matched source.

FDA application
NDA 206406

New drug application identity from the Orange Book snapshot.

Application holder
Veloxis Pharmaceuticals Inc

The listed applicant holds the FDA application; this field does not establish the product manufacturer.

Product presentations
3

Each FDA product number remains tied to its own strength, dosage form, route, and status.

Marketing categories
Prescription

Orange Book marketing categories do not establish real-time inventory or commercial availability.

Reference roles
RLD / RS

RLD and RS designations are presentation-specific, not inferred from the trade name.

TE codes
None posted

Therapeutic-equivalence codes apply only within the matching Orange Book product heading.

Listed patents
10

A zero means none appear in this snapshot, not that no patent rights exist.

Exclusivity records
0

FDA exclusivity and listed patent protection are distinct regulatory concepts.

Sourced from the official FDA Orange Book data file · snapshot refreshed

FDA product-presentation matrix

Every product number in this exact application
Every FDA product presentation under this application, with strength, dosage form and route, marketing status, therapeutic-equivalence code, and reference role.
ProductStrengthDosage form / routeMarketing statusTE codeReference role
001EQ 0.75MG BASETABLET, EXTENDED RELEASEORALPrescriptionNone posted
RLD
002EQ 1MG BASETABLET, EXTENDED RELEASEORALPrescriptionNone posted
RLD
003EQ 4MG BASETABLET, EXTENDED RELEASEORALPrescriptionNone posted
RLDRS

Marketing status, TE code, RLD, and RS are presentation-level fields. Never transfer one product number's designation to another presentation.

Who is responsible for this application?

Application holder is not the same as manufacturer

FDA application holder

Veloxis Pharmaceuticals Inc

The Orange Book identifies this organization as the applicant responsible for NDA 206406.

Manufacturer status

Not established by the Orange Book

A product-specific FDA label or NDC source must independently identify a manufacturer, labeler, distributor, packager, repackager, or relabeler. The applicant name is not used as a substitute for that evidence.

Regulatory interpretation

What the record means, and what it does not
FDA marketing status

3 presentations listed as prescription

RX and OTC are Orange Book marketing categories, not real-time inventory signals. Confirm current commercial availability with labeling, the application holder, or an authoritative drug listing.

Therapeutic equivalence

No TE code is posted for this application

No TE code does not mean FDA found the product ineffective or non-equivalent. FDA generally publishes TE evaluations for multisource prescription products; single-source and some other products may have no code.

Patent & exclusivity record

10 listed patent expirations and 0 exclusivity dates remain on or after Jul 26, 2026

The latest future date recorded across those files is Aug 30, 2028. Patent and FDA exclusivity operate independently, can overlap, and do not by themselves predict a generic launch date.

Same-ingredient landscape

20 other ANDAs and 5 other NDAs found

17 of the related ANDA applications are not marked discontinued. Sharing an ingredient does not establish pharmaceutical or therapeutic equivalence; strength, dosage form, route, and TE group still matter.

Which products are meaningfully comparable?

Exact ingredient + dosage form + route cohorts

NDA 206406 appears in 1 comparison cohort. These groups narrow the same-ingredient landscape, but strength and TE code must still match before interpreting therapeutic equivalence.

Tablet, Extended Release · Oral

Tacrolimus

1 application
Product rows
3
Active applications
1
Active with AB row
0

Why are clinical sections unavailable?

Exact application-label matching status
Exact source match queuedQueue NDA-206406

No exact application-level FDA or DailyMed label match has been reviewed for this application. Approved uses, dosing, warnings, adverse reactions, and clinical evidence remain unavailable rather than being inherited from a related brand, generic, or ingredient record.

Until an exact application match passes human review, this page intentionally omits approved uses, dosing, warnings, adverse reactions, mechanism, and clinical-study summaries. It never inherits those claims from an RLD, brand, generic, or same-ingredient product.

Strengths & dosage forms

3 approved presentations · NDA 206406
RLD
Strength
EQ 0.75MG BASE
Dosage form
TABLET, EXTENDED RELEASE
Route
ORAL
Marketing status
Prescription

Key dates

Approval, patents, exclusivity

  1. Approval

    FDA approval date of this drug product.

    11 yr 2 mo ago

  2. Today

  3. Patent 10166190 expires

    Listed drug product patent expiration.

    in 1 yr 10 mo

  4. Patent 10864199 expires

    Listed method-of-use patent (U-2678) expiration.

    in 1 yr 10 mo

  5. Patent 10864199 expires

    Listed method-of-use patent (U-2677) expiration.

    in 1 yr 10 mo

  6. Patent 11110081 expires

    Listed method-of-use patent (U-2678) expiration.

    in 1 yr 10 mo

  7. Patent 11123331 expires

    Listed method-of-use patent (U-2677) expiration.

    in 1 yr 10 mo

  8. Patent 11419823 expires

    Listed drug product patent expiration.

    in 1 yr 10 mo

  9. Patent 12083103 expires

    Listed method-of-use patent (U-2678) expiration.

    in 1 yr 10 mo

  10. Patent 12403095 expires

    Listed drug product patent expiration.

    in 1 yr 10 mo

  11. Patent 9549918 expires

    Listed drug product patent expiration.

    in 1 yr 10 mo

  12. Patent 8664239 expires

    Listed method-of-use patent (U-1752) expiration.

    in 2 yr 2 mo

  13. Patent 8664239 expires

    Listed method-of-use patent (U-2677) expiration.

    in 2 yr 2 mo

  14. Patent 8664239 expires

    Listed method-of-use patent (U-2678) expiration.

    in 2 yr 2 mo

  15. Patent 8685998 expires

    Listed drug product patent expiration.

    in 2 yr 2 mo

  16. Patent 8685998 expires

    Listed drug product patent expiration.

    in 2 yr 2 mo

  17. Patent 8685998 expires

    Listed drug product patent expiration.

    in 2 yr 2 mo

Patent & exclusivity timeline

Protection horizon
2026202720282029TodayPatent 10166190: 2028-05-30Patent 10166190Patent 10864199: 2028-05-30Patent 10864199Patent 10864199: 2028-05-30Patent 10864199Patent 11110081: 2028-05-30Patent 11110081Patent 11123331: 2028-05-30Patent 11123331Patent 11419823: 2028-05-30Patent 11419823Patent 12083103: 2028-05-30Patent 12083103Patent 12403095: 2028-05-30Patent 12403095Patent 9549918: 2028-05-30Patent 9549918Patent 8664239: 2028-08-30Patent 8664239Patent 8664239: 2028-08-30Patent 8664239Patent 8664239: 2028-08-30Patent 8664239Patent 8685998: 2028-08-30Patent 8685998Patent 8685998: 2028-08-30Patent 8685998Patent 8685998: 2028-08-30Patent 8685998
Patent expiryExclusivity endToday

Pharmaceutical detail

FDA product record

Active ingredient

TACROLIMUS

Strength

EQ 0.75MG BASE

Dosage form

TABLET, EXTENDED RELEASE

Route

ORAL

TE code

Not listed

Application

NDA 206406

Product number

001

Marketing status

Prescription

Reference listed drug (RLD)

Yes

Reference standard (RS)

No

Listed patents

Orange Book patent file
Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
10166190in 1 yr 10 mo
Product
10864199in 1 yr 10 mo
U-2678
10864199in 1 yr 10 mo
U-2677
11110081in 1 yr 10 mo
U-2678
11123331in 1 yr 10 mo
U-2677
11419823in 1 yr 10 mo
Product
12083103in 1 yr 10 mo
U-2678
12403095in 1 yr 10 mo
Product
9549918in 1 yr 10 mo
Product
8664239in 2 yr 2 mo
U-1752
8664239in 2 yr 2 mo
U-2677
8664239in 2 yr 2 mo
U-2678
8685998in 2 yr 2 mo
ProductU-1752
8685998in 2 yr 2 mo
ProductU-2678
8685998in 2 yr 2 mo
ProductU-2677

Active-ingredient family

Brand + generics

This is a reference-listed drug (RLD), the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

View full Tacrolimus family

How to use this record responsibly

Scope, limitations, and primary sources

What to verify before making a decision

  • The applicant is the holder of legal responsibility for the application; the Orange Book does not establish that the applicant manufactured or currently markets every listed product.
  • RX, OTC, and discontinued are FDA listing categories, not real-time pharmacy inventory or commercial-availability data.
  • Therapeutic equivalence applies only within the matching ingredient, dosage form, route, strength, and TE-code group; same ingredient alone is insufficient.
  • Listed patent and exclusivity dates are regulatory intelligence, not legal advice, a freedom-to-operate analysis, or a reliable generic-launch forecast.
  • The Orange Book is not prescribing information and does not provide indications, dosing, contraindications, adverse reactions, recalls, or current safety communications.

Official FDA references

Data shown here is normalized for search and comparison. When a regulatory, substitution, launch, or legal decision turns on a field, verify it against the current FDA record and the relevant source document.

Envarsus XR: frequently asked questions

Approval, therapeutic equivalence, patents, and exclusivity for this drug, from the FDA Orange Book.

Built directly from the FDA Orange Book product, patent, and exclusivity files refreshed Jul 02, 2026, 06:34 PM. Every strength of NDA 206406 is shown on this page. Interpret patents, exclusivity, availability, and therapeutic equivalence using the limitations above.

Related FDA reference tools

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.

Book a Demo